Ignite Creation Date:
2024-05-06 @ 5:07 PM
Last Modification Date:
2024-10-26 @ 2:22 PM
Study NCT ID:
NCT05191888
Status:
RECRUITING
Last Update Posted:
2022-01-14
First Post:
2021-12-28
Brief Title:
14-day PCAB-based High-dose Dual Therapy and14-day PCAB-based Triple Therapy vs 14-day PPI-based Reverse Hybrid Therapy
Sponsor:
Kaohsiung Medical University
Organization:
Kaohsiung Medical University
Study Overview
Official Title:
14-day PCAB-based and Reverse Hybrid Therapy Fro Helicobacter Pylori
Status:
RECRUITING
Status Verified Date:
2022-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
1 Test for Helicobacter pylori The test items include urease test histology bacterial culture serology and urea breath test At least two positive results can be used to confirm the diagnosis
2 To ensure that the research results are not artificially distorted this trial is a randomized study Random allocation which means that the subjects will use the random number table generated by a computer similar to the lottery to determine the treatment group accept one of the following schemes 111
2 To ensure that the research results are not artificially distorted this trial is a randomized study Random allocation which means that the subjects will use the random number table generated by a computer similar to the lottery to determine the treatment group accept one of the following schemes 111
Detailed Description:
Helicobacter pylori Hpylori infect more than 50 of humans globally This study were 1 to test whether the efficacies of 14-day PCAB-based high-dose dual therapy and 14-day PPI-based reverse hybrid therapy can achieve a higher eradication rate than 14-day PCAB-based triple therapy in the first-line treatment of H pylori infection 2 to compare the eradication rates of 14-day PCAB-based and PPI-based bismuth quadruple therapies in the second-line treatment of H pylori infection and 3 to examine the impacts of antibiotic resistance of H pylori as well as CYP3A4 CYP2C19 and IL-1B -511 genotypes of host on the eradication efficacies of anti-H pylori treatments
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None